Tags

Type your tag names separated by a space and hit enter

A Comprehensive Review on Preclinical Evidence-based Neuroprotective Potential of Bacopa monnieri against Parkinson's Disease.
Curr Drug Targets. 2022; 23(9):889-901.CD

Abstract

Parkinson's disease is a chronic and gradually progressive neurodegenerative disorder triggered due to the loss of dopamine-releasing neurons in the region of substantia nigra pars compacta characterized by the motor symptoms, such as tremor, bradykinesia, akinesia, and postural instability. Proteinopathies, mitochondrial dysfunction induced dopaminergic neuronal deterioration, and gene mutations are the hallmarks of Parkinson's disease. The bioactive components of Brahmi, such as Bacoside A, Bacoside B, and Bacosaponins, belong to various chemical families. Brahmi's neuroprotective role includes reducing neuronal oxidative stress, dopaminergic neuronal degeneration, mitochondrial dysfunction, inflammation, inhibition of α-synuclein aggregation, and improvement of cognitive and learning behaviour. Researchers found that Bacopa monnieri significantly increased brain levels of glutathione, vitamin C, vitamin E, and vitamin A in rats exposed to cigarette smoke. Brahmi has a potent antioxidant property and neuroprotective effects against PD that help reduce oxidative stress and neuroinflammation and enhance dopamine levels. The review collates all the preclinical studies that prove the beneficial neuroprotective effect of Brahmi for treating PD.

Authors+Show Affiliations

Institute of Pharmaceutical Research, GLA University, Mathura, U.P., India.Institute of Pharmaceutical Research, GLA University, Mathura, U.P., India.Institute of Pharmaceutical Research, GLA University, Mathura, U.P., India.Department of Pharmacology, School of Health Sciences, Central University of Punjab, Bathinda- 151001, Punjab, India.

Pub Type(s)

Journal Article
Review
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

35297345

Citation

Goyal, Ahsas, et al. "A Comprehensive Review On Preclinical Evidence-based Neuroprotective Potential of Bacopa Monnieri Against Parkinson's Disease." Current Drug Targets, vol. 23, no. 9, 2022, pp. 889-901.
Goyal A, Gopika S, Kumar A, et al. A Comprehensive Review on Preclinical Evidence-based Neuroprotective Potential of Bacopa monnieri against Parkinson's Disease. Curr Drug Targets. 2022;23(9):889-901.
Goyal, A., Gopika, S., Kumar, A., & Garabadu, D. (2022). A Comprehensive Review on Preclinical Evidence-based Neuroprotective Potential of Bacopa monnieri against Parkinson's Disease. Current Drug Targets, 23(9), 889-901. https://doi.org/10.2174/1389450123666220316091734
Goyal A, et al. A Comprehensive Review On Preclinical Evidence-based Neuroprotective Potential of Bacopa Monnieri Against Parkinson's Disease. Curr Drug Targets. 2022;23(9):889-901. PubMed PMID: 35297345.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A Comprehensive Review on Preclinical Evidence-based Neuroprotective Potential of Bacopa monnieri against Parkinson's Disease. AU - Goyal,Ahsas, AU - Gopika,Sainu, AU - Kumar,Abhishek, AU - Garabadu,Debapriya, PY - 2021/08/21/received PY - 2021/11/03/revised PY - 2021/12/30/accepted PY - 2022/3/18/pubmed PY - 2022/8/2/medline PY - 2022/3/17/entrez KW - Brahmi KW - Parkinson’s KW - anti-inflammatory KW - antioxidant KW - dopamine KW - neuroprotection SP - 889 EP - 901 JF - Current drug targets JO - Curr Drug Targets VL - 23 IS - 9 N2 - Parkinson's disease is a chronic and gradually progressive neurodegenerative disorder triggered due to the loss of dopamine-releasing neurons in the region of substantia nigra pars compacta characterized by the motor symptoms, such as tremor, bradykinesia, akinesia, and postural instability. Proteinopathies, mitochondrial dysfunction induced dopaminergic neuronal deterioration, and gene mutations are the hallmarks of Parkinson's disease. The bioactive components of Brahmi, such as Bacoside A, Bacoside B, and Bacosaponins, belong to various chemical families. Brahmi's neuroprotective role includes reducing neuronal oxidative stress, dopaminergic neuronal degeneration, mitochondrial dysfunction, inflammation, inhibition of α-synuclein aggregation, and improvement of cognitive and learning behaviour. Researchers found that Bacopa monnieri significantly increased brain levels of glutathione, vitamin C, vitamin E, and vitamin A in rats exposed to cigarette smoke. Brahmi has a potent antioxidant property and neuroprotective effects against PD that help reduce oxidative stress and neuroinflammation and enhance dopamine levels. The review collates all the preclinical studies that prove the beneficial neuroprotective effect of Brahmi for treating PD. SN - 1873-5592 UR - https://www.unboundmedicine.com/medline/citation/35297345/A_Comprehensive_Review_on_Preclinical_Evidence_based_Neuroprotective_Potential_of_Bacopa_monnieri_against_Parkinson's_Disease_ DB - PRIME DP - Unbound Medicine ER -